ReviewJournal of psychopharmacology (Oxford, England)2022
A narrative synthesis of research with 5-MeO-DMT.
Review in Journal of psychopharmacology (Oxford, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05698095 (A Phase 1, First-in-human, Double-blind, Placebo-controlled, Randomized, Single- and Multiple-ascending-dose Study to Determine the Safety, Tolerability, and Pharmacokinetics of 5-methoxy-N,N-dimethyltryptamine), which is not on this map. Cited by 38 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 1, First-in-human, Double-blind, Placebo-controlled, Randomized, Single- and Multiple-ascending-dose Study to Determine the Safety, Tolerability, and Pharmacokinetics of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) Administered by Intramuscular Injection in Healthy Subjects
Who cites it
38 citing papers in PubMed, 2 syntheses or guidelines pooled it, 74 citations in OpenAlex.
- Short-term safety and tolerability profile of 5-methoxy-N,N-dimethyltryptamine in human subjects: a systematic review of clinical trials.Frontiers in psychiatry · 2024Pooled it
- Drug-drug interactions involving classic psychedelics: A systematic review.Journal of psychopharmacology (Oxford, England) · 2024Pooled it
- Mapping the phenomenology of intranasal 5-MeO-DMT in psychedelic-naïve healthy adults.Scientific reports · 2025Trial
- Phase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy-Journal of psychopharmacology (Oxford, England) · 2024Trial
- Inhalable Psychedelic 5-MeO-DMT Shows Promise in Treatment-Resistant Depression.Journal of medicinal chemistry · 2026Article
- Speech markers of psychological change following a psychedelic 5-MeO-DMT retreat.Journal of psychopharmacology (Oxford, England) · 2026Article
- Short- and Long-Acting Psychedelics: Structure-Activity Relationships, Pharmacology, and Implications for Neuropsychiatric Therapeutics.ACS chemical neuroscience · 2026Review
- Serotonin Transporter Blockade Reduces the Psychedelic-Like Effects of 4-Methoxy-ACS chemical neuroscience · 2026Article
- Trials, trips, and tribulations: pathways for implementing psychedelic therapy in Ireland.The international journal of neuropsychopharmacology · 2026Review
- Vigilance state dissociation induced by 5-MeO-DMT in mice.Communications biology · 2026Article
- Flashbacks, Hallucinogen Persisting Perception Disorder (HPPD), and Reactivations Following the Use of Classic Psychedelics: Classification and Therapeutic Management.Current topics in behavioral neurosciences · 2026Review
- Illuminating consciousness.Frontiers in psychology · 2026Review
- Mind the gap! Addressing unresolved aspects of abuse potential evaluation and scheduling of classic and novel psychedelic drugs.Journal of psychopharmacology (Oxford, England) · 2026Review
- Toxicology and Pharmacological Interactions of Classic Psychedelics.Current topics in behavioral neurosciences · 2026Review
- Exploring New Frontiers in Pharmacological Treatment of Depression: A Review on Recent Advances.Current medicinal chemistry · 2026Review
- The psychedelic-peptide paradox: a hormetic hypothesis.Comprehensive psychoneuroendocrinology · 2025Review
- 5-MeO-DMT: An atypical psychedelic with unique pharmacology, phenomenology & risk?Psychopharmacology · 2025Review
- Diet and chemical defenses of the Sonoran Desert toad.PloS one · 2025Article
- Serotonergic psychedelic 5-MeO-DMT alters plasticity-related gene expression and generates anxiolytic effects in stressed mice.Molecular psychiatry · 2025Article
- On the varieties of conscious experiences: Altered Beliefs Under Psychedelics (ALBUS).Neuroscience of consciousness · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
background5-Methoxy-
methodsWe searched PubMed database for articles about 5-MeO-DMT. Search results were cross-checked against earlier reviews and reference lists were hand searched. Findings were synthesised using a narrative synthesis approach. This review covers the pharmacology, chemistry and metabolism of 5-MeO-DMT, as well epidemiological studies, and reported adverse and beneficial effects.
results5-MeO-DMT is serotonergic agonist, with highest affinity for 5-HT
conclusion5-MeO-DMT is a potentially useful addition to the psychedelic pharmacopoeia because of its short duration of action, relative lack of visual effects and putatively higher rates of ego-dissolution and mystical experiences. We conclude that further clinical exploration is warranted, using similar precautions as with other classic psychedelics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.